TrialThe Lancet. Respiratory medicine2016
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Jane C Davies et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
129 papers cite itlatest 60 shown
this paperpooled ittrialcites it